Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase - PubMed (original) (raw)

Review

. 2008 Jun;134(1-2):157-70.

doi: 10.1016/j.virusres.2007.12.018. Epub 2008 Mar 3.

Affiliations

• PMID: 18313784
• DOI: 10.1016/j.virusres.2007.12.018

Review

Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase

Jingshan Ren et al. Virus Res. 2008 Jun.

Abstract

The selection of drug resistant virus is a significant obstacle to the continued successful treatment of HIV infection. Reverse transcriptase is the target for numerous approved anti-HIV drugs including both nucleoside inhibitor (NRTI) and non-nucleosides (NNRTI). The many available crystal structures of RT reveal that, generally, in relation to their binding sites NRTI resistance mutations are generally more distally positioned, whilst for NNRTIs mutations are clustered. Such clustering implies a direct stereochemical basis for NNRTI resistance mechanisms, which is indeed observed in many cases such as the loss of key ring stacking interactions with inhibitors via mutations at Tyr181 and Tyr188. However, there are also indirect resistance mechanisms observed, e.g. V108I (via perturbation of Tyr188 and Tyr181) and K103N (apo-enzyme stabilisation). The resistance mechanism can be NNRTI-dependent as is the case for K101E where either indirect (nevirapine) or direct effects (efavirenz) apply. Structural studies have contributed to the design of newer generation NNRTIs and identified a number of features which may contribute to their much improved resistance profiles. Such factors include reduced interactions with Tyr181, the presence of inhibitor/main-chain H-bonds and ability to undergo conformational flexing and rearrangement within the mutated drug site.

PubMed Disclaimer

Similar articles

• Structural insights into mechanisms of non-nucleoside drug resistance for HIV-1 reverse transcriptases mutated at codons 101 or 138.
  Ren J, Nichols CE, Stamp A, Chamberlain PP, Ferris R, Weaver KL, Short SA, Stammers DK. Ren J, et al. FEBS J. 2006 Aug;273(16):3850-60. doi: 10.1111/j.1742-4658.2006.05392.x. FEBS J. 2006. PMID: 16911530
• Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors.
  Ren J, Nichols C, Bird L, Chamberlain P, Weaver K, Short S, Stuart DI, Stammers DK. Ren J, et al. J Mol Biol. 2001 Sep 28;312(4):795-805. doi: 10.1006/jmbi.2001.4988. J Mol Biol. 2001. PMID: 11575933
• Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors.
  Ren J, Nichols CE, Chamberlain PP, Weaver KL, Short SA, Stammers DK. Ren J, et al. J Mol Biol. 2004 Feb 20;336(3):569-78. doi: 10.1016/j.jmb.2003.12.055. J Mol Biol. 2004. PMID: 15095972
• Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future.
  De Clercq E. De Clercq E. Chem Biodivers. 2004 Jan;1(1):44-64. doi: 10.1002/cbdv.200490012. Chem Biodivers. 2004. PMID: 17191775 Review.
• Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase.
  Menéndez-Arias L. Menéndez-Arias L. Virus Res. 2008 Jun;134(1-2):124-46. doi: 10.1016/j.virusres.2007.12.015. Epub 2008 Feb 12. Virus Res. 2008. PMID: 18272247 Review.

Cited by

• The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.
  Xu HT, Colby-Germinario SP, Oliveira M, Han Y, Quan Y, Zanichelli V, Wainberg MA. Xu HT, et al. J Virol. 2014 Feb;88(3):1536-47. doi: 10.1128/JVI.02904-13. Epub 2013 Nov 13. J Virol. 2014. PMID: 24227862 Free PMC article.
• Effects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors.
  Xu HT, Colby-Germinario SP, Oliveira M, Rajotte D, Bethell R, Wainberg MA. Xu HT, et al. Antimicrob Agents Chemother. 2014 Aug;58(8):4515-26. doi: 10.1128/AAC.02729-14. Epub 2014 May 27. Antimicrob Agents Chemother. 2014. PMID: 24867966 Free PMC article.
• Pyridones as NNRTIs against HIV-1 mutants: 3D-QSAR and protein informatics.
  Debnath U, Verma S, Jain S, Katti SB, Prabhakar YS. Debnath U, et al. J Comput Aided Mol Des. 2013 Jul;27(7):637-54. doi: 10.1007/s10822-013-9667-1. Epub 2013 Jul 25. J Comput Aided Mol Des. 2013. PMID: 23884707
• Ligand similarity guided receptor selection enhances docking accuracy and recall for non-nucleoside HIV reverse transcriptase inhibitors.
  Stanton RA, Nettles JH, Schinazi RF. Stanton RA, et al. J Mol Model. 2015 Nov;21(11):282. doi: 10.1007/s00894-015-2826-7. Epub 2015 Oct 8. J Mol Model. 2015. PMID: 26450349 Free PMC article.
• Complexes of HIV-1 RT, NNRTI and RNA/DNA hybrid reveal a structure compatible with RNA degradation.
  Lapkouski M, Tian L, Miller JT, Le Grice SFJ, Yang W. Lapkouski M, et al. Nat Struct Mol Biol. 2013 Feb;20(2):230-236. doi: 10.1038/nsmb.2485. Epub 2013 Jan 13. Nat Struct Mol Biol. 2013. PMID: 23314251 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database